- Open Access
PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Journal of Experimental & Clinical Cancer Research volume 38, Article number: 256 (2019)
Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies, including breast cancer (BC). However, whether the PTENP1/miR-20a/PTEN axis exists and how it functions in BC progression remains elusive.
The levels of PTENP1, PTEN and miR-20a were measured by qRT-PCR. Furthermore, the breast cancer cells proliferation was further measured by CCK8 assay, colony formation assays, EDU and Ki67 staining. The migratory and invasive ability was determined by transwell assay. Flow cytometry, JC-1 and TUNEL assays were conducted to show the occurrence of apoptosis. Xenograft model was used to show the tumorigenesis of breast cancer cells.
We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis. Moreover, alteration of PTENP1 affects BC cell proliferation, invasion, tumorigenesis and chemoresistance to adriamycin (ADR). Bioinformatic analysis and dual-luciferase reporter gene assay predicted that PTENP1 was a direct target of miR-20a, which was clarified an alternative effect on BC aggressiveness phenotype. In addition, PTENP1 functioned as an endogenous sponge of miR-20a to regulate PTEN expression, which mediated BC cells proliferation, invasion and drug resistance via activation the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. PI3K inhibitor LY294002 or siAkt also prevented BC cells progression.
Collectively, these data indicated that PTENP1/miR-20a/PTEN axis involved in the malignant behaviors of BC cells, illuminating the possible mechanism mediated by PTEN via PI3K/Akt pathway. Targeting PTENP1/miR-20a/PTEN may provide a potential diagnosis and treatment strategy for BC.
Breast cancer (BC) is the most common cause of cancer mortality among women, accounting for 16% of cancer deaths in adult women . Despite improvements in the prognosis of BC seen in recent decades, additional therapeutic advances are needed, particularly for patients with metastatic/advanced disease . Furthermore, the drug resistance in the course of chemotherapy has brought great threat to breast cancer patients , especially as chemoresistance limits the effectiveness of chemotherapeutic agents to a large extent. Therefore, it is imperative to clarify the underlying molecular mechanism during BC progression.
Long non-coding RNAs (LncRNAs) are defined as a class of non-protein coding transcripts over 200 nucleotides, and are now emerging as crucial regulators of cellular processes and diseases, and their aberrant transcription can lead to altered expression of target genes involved in cancer pathways and functions . By binding to the associated gene of cancer, lncRNAs function as oncogenes or tumor suppressors in human cancer. For example, lncRNA PTENP1, the pseudogene of PTEN tumor suppressor, contains a highly homologous region upstream of the 3′UTR of PTEN, can regulate PTEN expression, thus exerts an effect on the process of carcinogenesis . PTENP1 also participates in repressing cell proliferation, inhibiting migration, and promoting apoptosis [6, 7]. Recent studies have shown that lncRNAs, as competing endogenous RNAs (ceRNA), play important roles in modulating miRNA function through binding sites . Enhanced PTENP1 could inhibit BC cell growth, metastasis and tumourigenicity by inhibiting miR-19b and facilitating PTEN in BC . Consequently, miRNAs further affect the downstream protein-coding genes by binding to its 3′-UTR. Wei et al. showed that miR-130a as an oncogenic miRNA that targets PTEN to drive malignant cell survival and tumor growth . MiR-20a acts as a negative regulator of PTEN, and mediates the proliferation, migration and apoptosis of multiple myeloma . Similarly, we have found that PTENP1 influences the biological function of miR-20a in BC progression.
The PI3K/Akt pathway is activated subsequent to RTK activation. Hyperactivation of PI3K/Akt signaling has been reported in many types of human cancers, thus targeting the regulators in this pathway has attractive therapeutic potential . Ectopic expression of PTENP1 resultes in the upregulation of PTEN, accompanies by the blockage of PI3K/Akt pathway and growth inhibition in prostate and renal cancer cells [12, 13]. MiR-106b and miR-93 regulate BC cell migration, invasion and proliferation by suppression of PTEN via PI3K/Akt pathway, which could be blocked by upregulation of PTEN . MiR-130b targets PTEN to reduce drug resistance, proliferation and apoptosis of BC cells via the PI3K/Akt pathway . However, PTENP1 and miR-20a affect PTEN, an important process in BC progression, is not clear.
In the present study, the association of downregulated PTENP1 and PTEN and BC progression was examined. LncRNA PTENP1 was evaluated as a molecular sponge for miR-20a, and these ncRNAs further regulated PTEN. Relative function mechanism assays revealed that PTENP1/miR-20a/PTEN axis exerted its function in BC partly through PI3K/Akt signaling pathway.
Materials and methods
Samples from BC patients
A total of 52 previously diagnostic BC patients who received surgical operation at the First Affiliated Hospital of Dalian Medical University from April 2014 to January 2018 were enrolled in this study. The study and its informed consent have been examined and certified by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (YJ-KY-FB-2017-32). In accordance with the International Union against Cancer (UICC), the samples were identified BC tissues and their adjacent noncancerous tissues. The samples were maintained in liquid nitrogen for later experiments.
The human BC cell lines MDA-MB-231, T-47D and MCF-7 were obtained from KeygenBiotech Co. Ltd. (Nanjing, China). The mammary epithelium MCF-10A was purchased from ATCC cell banking. The BC cells were cultured in DMEM, supplied with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA) at 37 °C in a humidified and 5% CO2 incubator. MCF-10A cells were maintained in DMEM-F12 media supplemented with hydrocortisone (0.5 μg/ml), insulin (10 μg/ml), hEGF (20 ng/ml) and 10% (v/v) FBS. Adriamycin (Sigma, St Louis, MO, USA) was added to parental cell cultures in stepwise increasing concentrations from 1 mg/l to 5 mg/l for 2 months to develop an adriamycin-resistant (ADR) subline, named MCF-7/ADR and T47D/ADR, correspondingly. To maintain the resistant phenotype, MCF-7/ADR and T47D/ADR cells were kept in the medium containing 1 mg/l adriamycin (ADR) and were cultured in drug-free medium for 48 h before the experiments.
Real-time PCR analysis
Total RNA was isolated from tissues and BC cell lines by RNeasy Mini Kit (Qiagen, Valencia, CA). RNA was reverse transcribed to cDNA using Reverse Transcription Kit (Invitrogen, CA, USA). The qRT-PCR was performed under an ABI Prism7500 fast real-time PCR system (Applied Biosystems, Foster City, CA) with mixing a QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA). Relative RNA expression was calculated by ΔΔCt method with normalization to U6 small nuclear RNA.
Western blot analysis
Total cell lysates were prepared with RIPA lysis buffer (KeyGEN, Nanjing, China). The proteins were separated by 10% SDS-PAGE gels and then transferred to PVDF membranes (Millipore, Bedford, MA, USA). TBST with 5% skim milk powder was used for blocking the PVDF membranes. Then, the blots were incubated with different primary antibodies at 4 °C overnight. After incubating with secondary antibodies, the bands were detected by an ECL Western blot kit (Thermo Fisher Scientific, USA) and analyzed by LabWorks (TM ver4.6, UVP, BioImaging Systems, NY, USA). GAPDH was used as control.
Cell transfection and RNA interference
PCR production of PTEN ampliation was cloned into pmirGLO vector (Promega). MiR-20a mimic, inhibitor and miR-NC were synthesized by GenePharma Co.Ltd. (Suzhou, China). LncRNA PTENP1 pcDNA3.1 vector (PTENP1, Invitrogen, CA, USA), LV-NC, LV-PTENP1, siPTENP1, shPTENP1, siAkt, siSCR and shSCR were obtained from GenePharma Co.Ltd. (Suzhou, China). The transfection assay was conducted with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for incubation. The transfected efficiency was measured by qRT-PCR.
Dual luciferase reporter gene assay
A pmirGLO Dual-Luciferase miRNA Target Expression Vector was purchased from GenePharma Co.Ltd. (Suzhou, China). Firefly luciferase functioned as primary reporter to regulate mRNA expression, and renilla luciferase was used as a normalized control. Co-transfection was conducted with lipofectamine 2000 for 48 h, the dual luciferase reporter assay system (Promega) was utilized according to the manufacturer’s instruction. The relative luciferase activity was calculated as the ratio of frefly luciferase activity versus renilla luciferase activity. Data were shown as the mean value ± SD and each experiment was performed thrice.
Cell proliferative ability was investigated by using cell counting kit-8 (CCK-8; Dojindo, Japan). Cells (1 × 103 per well) were plated into 96-well plate with the corresponding medium, and cultured in a humidified incubator at 37 °C. 11 μLCCK8 were added into the plate for 4 h. The spectrometric absorbance was measured by microplate reader (Model 680; Bio-199 Rad, Hercules, CA, USA) at 490 nm.
The drug resistance to ADR was detected by CCK-8. Different concentration of ADR was added into 96-well plate after seeding the cells. Similarly, the absorbance was then measured to evaluate the drug resistance to ADR of BC cells. Each experiment was performed thrice.
Focus formation assay
Single-cell suspension was obtained and then seeded in 6-well plate with 1 × 103 per well. The medium was changed every 4 days. 12 days later, the foci were formed obviously. The colonies were fixed by 4% paraformaldehyde for 20 min, and then stained with 0.2% crystal violet. The colonies were photographed and counted.
Cell invasion assay
Cell invasive ability was measured using ECMatrix gel (Chemicon)-coated transwell inserts, respectively (Trevigen, City of Gaithersburg, Maryland, USA). 5 × 104 cells were harvested in serum-free DMEM and added to the upper chamber. Medium containing 10% FCS was added to the bottom chamber, and cells were allowed to invade for 24 h at 37 °C. The upper side cells were removed by a cotton swab. The invading cells were counted to estimate the invasive capacity. Five random fields were analyzed for each chamber.
Flow cytometry analysis
Cells were incubated with different concentration of ADR for 48 h. Annexin-V-FITC apoptosis detection kit (BD, Franklin Lakes, NJ, USA) was used to measure cell apoptosis. 2 × 103 cells were harvested and adjusted in 100 μL binding buffer. Annexin V and propidium iodide were used to stain for 10 min avoiding lights, and 400 μL binding buffer was added into the cell suspension. The apoptosis cells were detected by FACS Calibur (Becton-Dickinson, CA, USA).
BC cells were added in culture dishes and fixed with 4% paraformaldehyde for 20 min. BC cells were treated with 0.2% Triton X-100 for 3 min, and incubated with 5% BSA for 1 h. The primary antibody was added into the dish overnight at 4 °C. Slides were then washed three times with PBS and incubated 1 h with secondary antibody. The cells were stained by 4, 6-diamino-2-phenylindole (DAPI, Sigma-Aldrich, St Louis, MO, USA) in PBS for nuclear staining. Images were taken in a Carl Zeiss fluorescent microscope (Carl Zeiss Microscopy).
TUNEL assay (terminal deoxynucleotidyl transferase dUTP nick end labelling)
TUNEL assay was carried out to measure the fragmented DNA of apoptotic cells. Apoptotic cells were induced by ADR, and fixed by 4% formaldehyde for 25 min at 4 °C. The cells were permeabilized by 0.2% TritonX-100 for 5 min. Then the cells were equilibrated with 100 μL Equilibration buffer for 10 min at room temperature. Cellswere labeled with 50 μL TdT reaction mix at 37 °C for 1 h. SSC buffer was used to stop the reaction and stained nuclei with DAPI. The images were obtained by fluorescence microscopy.
RNA immunoprecipitation (RIP) assay
The Magna RIPTM RNA Binding Protein Immunoprecipitation Kit (Millipore, USA) was used to conduct RNA immunoprecipitation (RIP) assay. The endogenous miR-20a which combined with PTENP1 was pulled down. The cell lysis were collected and incubated in RIP buffer containing magnetic bead conjugated to either a human anti-Ago2 antibody (Millipore) or negative control IgG and was used to precipitate the cell extracts. The expression levels of PTENP1 and miR-20a in the precipitates were analyzed by qPCR.
In vivo antitumor activity
4-week-old female athymic nude mice were purchased from the Model Animal Research Institute of Nanjing University. Approximately, 1 × 107 cells were injected subcutaneously into the right flank of each nude mouse, respectively. In addition, to evaluate the chemosensitivity effect of PTENP1, the treatment groups received 7 mg/kg ADR i.p. three times a week for 3 weeks. The mice were humanely killed and their tumors were photographed. The tumor volume was calculated. These experiments were approved by the Committee on the Ethics of Animal Experiments of the Dalian Medical University, China.
Immunohistochemistry (IHC) staining
Human BC samples and xenograft tumors were collected and performed on paraffin-embedded sections. 4 μm-thick sections were deparaffinized, rehydrated and then immersed with 3% hydrogen peroxide for 10 min to quench endogenous peroxidase and labeled with antibodies at 4 °C overnight. The slides were stained with the secondary streptavidin-horseradish peroxidase-conjugated antibody (Santa Cruz Biotech, Santa Cruz, CA) for 1 h. The slides were then counterstained with hematoxylin for 30s and cover slipped.
Data were expressed as means ± standard deviation (SD). SPSS 17.0 software was used to analyze the experimental data. Student’s t-test was performed to compare two different groups. The one-way analysis of variance (ANOVA) was used to determine the significant difference of multiple groups. The survival curves were calculated by Kaplan-Meier method, and the difference was assessed by a log-rank test. Spearman’s correlation analysis was used to identify the association between miRNAs and mRNA expression. P < 0.05 was considered statistically signifcant.
PTENP1 and PTEN are concomitantly downregulated in BC tissues and cell lines
Researchers have shown PTENP1 to be lost or downregulated in various cancers. To evaluate PTENP1 status in BC, we examined PTENP1 expression between 52 pairs of BC tissues and the corresponding adjacent tissues from the same patients. PTENP1 showed a lower level in tumor tissues relative to the paired adjacent tissues (Fig. 1a). The expression of PTEN, the parental gene of PTENP1, in the same paired biopsies was reduced in tumor tissues (Fig. 1a). In addition, the identical condition was also observed in the cell level of BC (Fig. 1b). Down expression of PTENP1 and PTEN was confirmed in MDA-MB-231 and ADR resistant BC cell MCF7/ADR and T47D/ADR.
We next examined the significance of PTENP1 and PTEN expression correlated to the pathological features of BC patients. PTENP1 and PTEN levels were closely correlated with advanced BC stages, and BC patients on stage III and IV exhibited lower PTENP1 and PTEN levels (Fig. 1c). Kaplan-Meier analysis was used to analyze the correlation between PTENP1 or PTEN expression and the overall survival rate. As shown in Fig. 1d, the PTENP1 or PTEN downregulated patients showed signifcant poor prognosis.
To better understand the role of PTENP1 in BC progression, we manipulated the expression of PTENP1 by transfecting PTENP1 or siPTENP1 in BC cell lines. As shown in Fig. 1e and f, PTENP1 was significantly upregulated in transfected MDA-MB-231, MCF7/ADR and T47D/ADR cells, and siPTENP1 effectively inhibited the endogenous PTENP1 level in MCF-7 and T47D cells. In addition, the length of PTENP1 and the non-coding potential also identified through online bioinformatic tools (Additional file 1: Figure S1). These data indicated that low levels of PTENP1 and PTEN might promote the BC progression and associate with the poor clinical prognosis.
Overexpression of PTENP1 suppresses BC progression
In order to explore the functional signifcance of PTENP1 upregulation on BC cell progression, CCK8 assays were used to identify the growth rate of BC cells. The results indicated that overexpression of PTENP1 attenuated BC cell viability (Fig. 2a). The colony formation assay also proved a decreased tendency after BC cells transfected with PTENP1 (Fig. 2b). Moreover, Edu showed a remarkable function in evaluating cell proliferation, which usually was involved in DNA synthesis. The merged images were presented, and showed that overexpression of PTENP1 reduced BC cells proliferation (Fig. 2c). In accordance with Edu staining, Ki67 expressed a weaken fluorescence intensity in BC cells transfected with PTENP1 (Fig. 2d), indicating that PTENP1 overexpression could inhibit BC cell growth. As shown in Fig. 2e, high PTENP1 level impeded the migratory and invasive capability of MDA-MB-231 cell compared to the cell transfected with vector, further demonstrating a tumor suppressive role of PTENP1 in BC cells.
Following PTENP1 overexpression, the reversal chemoresistance caused by PTENP1 was performed. Interestingly, when PTENP1 overexpression cells were incubated with the presence of the chemotherapeutic agent ADR, the cells demonstrated a reduced capability to proliferate compared with their control groups (Fig. 2f). The IC50 values were significantly decreased in PTENP1 overexpression groups compared with the controls (Fig. 2g). In response to ADR treatment, overexpressed PTENP1 attenuated the resistant cell colony formation (Fig. 2h), suggesting that PTENP1 overexpression in combination with chemotherapy might be a potentially viable treatment strategy. Moreover, upregulation of PTENP1 significantly enhanced the ability of chemotherapy-induced apoptosis in BC cell lines (Fig. 2i). The collapse of mitochondrial tansmembrane potential showed the occurrence of apoptosis. Mitochondrial membrane potential damage was a key event during the occurrence of apoptosis, which was caused by the activation of caspases, and cytochrome c released into cytosol. JC-1 content was detected by immunofluorescence staining, indicating the apoptosis caused by overexpressed PTENP1 (Fig. 2j). High fluorescence intensity was captured during the apoptosis occurred after overexpressing PTENP1 by fluorescence microscope (Fig. 2k). Apoptosis was also assessed by the appearance of caspase-3 cleavage after western blot. As shown in Fig. 2l, with drug treatment, BC cell lines transfected with PTENP1 expressed increased levels of cleaved caspase3 and cleaved PARP1, and decreased caspase3 and PARP1.
To further assess the chemosensitivity to ADR in vivo, mouse xenograft studies were performed. Overexpressed PTENP1 significantly inhibited tumor growth. In a further study in the ADR treatment PTENP1 overexpression model, the primary tumor volume was found to decrease with ADR treatment but overall the decrease was at a significantly faster rate than the untreated group (Fig. 2m), suggesting the effect of PTENP1-mediated function concomitant application of ADR in vivo. As shown in Fig. 2n, the expression of PTEN and Ki67 in xenograft tumor was also verified by IHC staining. Thus, overexpression of PTENP1 modulated BC cell proliferation, metastasis, apoptosis and tumorigenicity, as well as exhibited more sensitive to ADR.
Low PTENP1 level enhances the malignant behavior of BC cells
To decipher the biological function of PTENP1 by forcing its expression in MCF-7 and T47D cells, downexpression of PTENP1 led to an increase in cell growth (Fig. 3a). In accordance with the findings of the proliferation assay, the colony numbers of siPTENP1 cells were remarkably increased (Fig. 3b). To intuitively observe the proliferation in BC cells with low PTENP1 expression, Edu staining (Fig. 3c) and Ki67 (Fig. 3d) staining were carried out. As shown in Fig. 3e, MCF-7 transfected with siPTENP1 obtained a more aggressive characteristic than the cells transfected with siSCR. For this part, we identified the inhibitory role of PTENP1 in BC malignancy.
Furthermore, down-expression of PTENP1 promoted MCF-7 and T47D cell chemoresistance to ADR (Fig. 3f). IC50 values were significantly higher in the siPTENP1 transfected cells than the control group (Fig. 3g). Colony formation assay further proved MCF-7 and T47D cell lines had a variable degree in response to chemotherapeutic treatment (Fig. 3h). In addition, the ADR significantly induced apoptosis in the both cell lines (Fig. 3i). JC-1 staining also showed an increased J-aggregates in CRC cells transfected with siPTENP1 (Fig. 3j). Moreover, TUNEL assay showed less occurrence of apoptosis after transfecting siPTENP1 (Fig. 3k). Altered level of full length caspase3, PARP1, cleaved caspase3 and cleaved PARP1 were also detected by western blot, suggesting that apoptosis indeed occurred (Fig. 3l).
Next, the antitumor activity of ADR against PTENP1-driven tumor growth in nude mice was also assessed. ADR treatment significantly reduced MCF-7 tumor growth (Fig. 3m). IHC staining was performed on tumors to indicate the expression of PTEN and Ki67 in tumors (Fig. 3n). Therefore, downregulation of PTENP1 promoted BC cell proliferation, metastasis and cell survival in response to ADR.
PTENP1 is a direct target of miR-20a and a positive regulator of PTEN
Recently, ceRNA have generated substantial interest and have been reported in many cancers. Bioinformatic analysis predicts that miR-20a is closely associated with PTENP1. Interestingly, miR-20a showed certain difference between BC tissues and the adjacent tissues (Fig. 4a). Furthermore, MDA-MB-231 and ADR resistant BC cells revealed increased miR-20a level (Fig. 4b), indicating that miR-20a was frequently up-regulated in BC. A significant negative correlation was observed between PTENP1 and miR-20a expression (Fig. 4c). According to the bioinformatic analysis, we determined the predicted binding sites. Dual-luciferase reporter gene assay confirmed that PTENP1 was a direct target of miR-20a (Fig. 4d). MiR-20a mimic decreased the PTENP1 level in MCF-7 and T47D cells (Fig. 4e). In contrast, anti-miR-20a dramatically up-regulated PTENP1 expression in MDA-MB-231, MCF-7/ADR and T47D/ADR cells (Fig. 4f), indicating miR-20a could be a negative regulator of PTENP1. To verify whether PTENP1 associates with miRNP, RIP assay was performed on BC cell line extracts using anti-Ago2 antibody. PTENP1 and miR-20a were significantly enriched in Ago2-containing immunoprecipitate compared with control immunoglobulin G (IgG) immunoprecipitate (Fig. 4g), providing further evidence to the association of PTENP1 and miR-20a.
Next, pearson correlation coefficient analysis showed a significant negative correlation between miR-20a and PTEN in BC patients (Fig. 4h). We also performed dual-luciferase assay to confirm the interaction between miR-20a and PTEN (Fig. 4i), confirming that PTEN was a direct target of miR-20a. MiR-20a mimic significantly decreased expression of PTEN in MCF-7 and T47D cells (Fig. 4j). MiR-20a inhibitor also increased PTEN expression (Fig. 4k), indicating that there was a strong inverse correlation between expression of PTEN and miR-20a. PTENP1 might act as a tumor suppressor by endogenously competing with miR-20a, recovering the suppressed function of PTEN in BC.
MiR-20a reverses the tumor suppressive function of PTENP1 by regulating PTEN expression in BC progression
To investigate the relationships among PTENP1, miR-20a and PTEN and their effects on the BC development, we overexpressed PTENP1 and miR-20a in MDA-MB-231 and MCF-7/ADR cells. The mRNA and protein levels of PTEN were down-regulated by miR-20a mimic in these cells, whereas PTENP1 overexpression enhanced PTEN level. Co-transfection of miR-20a and PTENP1 showed that miR-20a partially abrogated the increase in PTEN level by PTENP1, suggesting that PTENP1 regulated the miR-20a target gene PTEN (Fig. 5a, b). Cell viability was significantly decreased in BC cells transfected with PTENP1, whereas the viability was reversed with co-transfection with miR-20a (Fig. 5c). Colony formation assay also depicted low numbers in BC cells transfected with PTENP1, and the colony formation ability was regained with transfected miR-20a mimic (Fig. 5d). As shown in Fig. 5e, in comparison to the control, MDA-MB-231 transfected with PTENP1 exhibited low aggressiveness, which was increased in MDA-MB-231 transfected with miR-20a. However, co-transfected PTENP1 and miR-20a depicted a revised migration and invasion than the cell only transfected with PTENP1.
To determine whether up-regulated PTENP1 and miR-20a were critical for MCF-7/ADR growth following ADR treatment, drug susceptibility assay was performed. As demonstrated in Fig. 5f, miR-20a mimic promoted MCF-7/ADR cell growth after ADR treatment. Interestingly, up-regulated PTENP1 inhibited the growth of MCF-7/ADR cells, and this growth could be reversed by miR-20a mimic. Furthermore, the IC50 of ADR on MCF-7/ADR cells was detected (Fig. 5g). With ADR treatment, the colony formation number was counted (Fig. 5h). Finally, cell apoptosis induced by PTENP1 or miR-20a in MCF-7/ADR cells after ADR treatment was detected by FCM (Fig. 5i). In short, all the outcomes above explained the function and regulatory mechanism of PTENP1/miR-20a/PTEN axis in the BC development.
Inhibition of miR-20a reverses the promotional effect of siPTENP1 by mediating PTEN expression in BC progression
To further determine the role of PTENP1-miR-20a-PTEN axis in BC progression, we down-regulated the expression of PTENP1 and miR-20a in MCF-7 and T47D cells. Increased PTEN was detected in the cells transfected with miR-20a inhibitor, and knockdown of PTENP1 decreased PTEN expression in BC cell lines (Fig. 6a, b). Co-transfection of anti-miR-20a and siPTENP1 showed that anti-miR-20a partially restored the suppression of PTEN level by siPTENP1. The growth rate was much higher in the cells transfected with siPTENP1, and lower in the cells transfected with miR-26a inhibitor than the control groups. Co-transfection of anti-miR-20a and siPTENP1showed that anti-miR-20a suppressed the proliferation promoted by siPTENP1 (Fig. 6c). Colony formation assay also depicted the same tendency (Fig. 6d). The migratory and invasive abilities were also reconsolidated by transfection with anti-miR-20a, siPTENP1 or co-transfection (Fig. 6e).
Furthermore, the potential function of PTENP1-miR-20a-PTEN pathway to ADR resistance was evaluated. The MCF-7 cells became sensitive to ADR after anti-miR-20a, while cells transfected with siPTENP1 remained resistant to ADR. Anti-miR-20a attenuated the cell sensibility to ADR induced by siPTENP1 (Fig. 6f). The IC50 values showed similar tendency (Fig. 6g). Colony formation assay further proved MCF-7 cells had a variable degree in response to ADR treatment (Fig. 6h). As shown Fig. 6i, treatment with ADR, anti-miR-20a reduced cell apoptosis, whereas siPTENP1 promoted apoptosis. Co-transfection of anti-miR-20a and siPTENP1 showed that anti-miR-20a restored apoptosis promoted by siPTENP1. These data suggest that miR-20a reverses the antitumor effect of siPTENP1 by regulating PTEN in BC progression.
PTENP1/miR-20a/PTEN axis activates PI3K/Akt pathway in PI3K/Akt- mediated BC cell progression
Next, to investigate whether the PTENP1/miR-20a/PTEN axis could regulate PI3K/Akt signaling, we examined the effect of PTENP1/miR-20a/PTEN axis on the phosphorylation levels of PI3K/Akt pathway in BC cells. As shown in Fig. 7a, overexpressed miR-20a promoted PI3K/Akt signal activity in MDA-MB-231 cells. Upregulation of PTENP1 attenuated the pathway activation. However, co-transfection of miR-20a and PTENP1 in MDA-MB-231 cells significantly reversed the activity of pathway in relation to the cells transfected with miR-20a or PTENP1. Similarly, co-transfection of inmiR-20a and siPTENP1 in HCT-8/5-FU cells revealed a reversal effect on the phosphorylated status in the cells transfected inmiR-20a or siPTENP1 alone (Fig. 7b). Moreover, regulation of miR-20a and PTENP1 affected PTEN level, exhibiting regulatory role of PTENP1/miR-20a/PTEN axis in PI3K/Akt signaling.
To further understand the significance of PI3K/Akt pathway in BC progression, MDA-MB-231 cells were treated with PI3K inhibitor (LY294002) or siAkt. Treatment with LY294002 or siAkt significantly inhibited the phosphorylation of PI3K/Akt pathway in MDA-MB-231 cells (Fig. 7c). Accordingly, the proliferative rates and invasive ability were decreased in MDA-MB-231 cells treated with LY294002 or siAkt than the control cells (Fig. 7d). In addition, combination of siAkt and PTENP1 showed decreased cell proliferation and aggressiveness. Moreover, siAkt induced highly apoptotic cell rates compared to the siSCR group, demonstrating the potential utilization of PTENP1 for clinical BC targeting therapy (Additional file 2: Figure S2). These results suggested that PTENP1/miR-20a/PTEN axis could mediate the metastatic ability of cancer cells possibly by affecting PI3K/Akt activation.
Metastasis and chemoresistance lead to the treatment failure of BC patients. Interestingly, lncRNAs are reported to be critical regulators involved in tumour-related progression. Thus, we investigated the ceRNA-dependent role of the lncRNA PTENP1 in the development of BC. This study provided us the first clarification into the potential mechanism that PTENP1-miR-20a-PTEN network modulated the BC progression via PI3K/AKT pathway.
Recently, lncRNA PTENP1 and PTEN expression were found to be decreased in some cancer types, including hepatocellular carcinoma (HCC) , gastric cancer  and head and neck squamous cell carcinoma (HNSCC) . We assessed PTENP1 and PTEN expression in BC tissues and cell lines, and the results showed down-regulation in BC tissues compared with adjacent normal tissues. In line with the results of our study, Li et al. reported decreased PTENP1 expression in BC cells, indicating such a decrease in expression may be important in oncogenesis . Furthermore, our study also found low expression of PTENP1 and PTEN to be closely related to advanced TNM stage and overall survival in BC. Low levels of PTENP1 have been correlated with worse overall survival and disease-free survival rates of HNSCC patients , consistent with our results. Dysregulation of lncRNAs often led to the tumorigenesis and the malignant progression. PTENP1 over-expression resulted in the growth inhibition of cancer cells both in vitro and in vivo, suggesting that PTENP1 played a tumor suppressive role in HCC . In esophageal squamous cell carcinoma (ESCC), overexpression of PTENP1 resulted in inhibited proliferation . In the present study, we found that ectopic expression of PTENP1 led to inhibition of the tumor growth, colony formation, invasion and xenograft tumor growth of BC. Our results indicated that PTENP1 might function as potential therapy target of BC.
Recent evidence has suggested that competitive endogenous RNAs (ceRNAs) are important regulatory molecules in cancer and their dysregulation may contribute to cancer pathogenesis. For example, enhanced PTENP1 could inhibit BC cell growth, metastasis and tumourigenicity by inhibiting miR-19b and facilitating PTEN in BC . MiR-19b and miR-20a were members of crucial oncogene miR-17-92 clusters. Although similar oncogenetic effects of miR-20a and 19b were existed on tumor procession, the overall BC cell malignancy should be better verified. In gastric cancer, PTENP1 was confirmed by binding miR-106b/ miR-93, in a ceRNA modulation manner, further affected PTEN level . PTENP1 acted as a competing endogenous RNA to protect PTEN transcripts from being inhibited by miR-21, and consequently inhibited proliferation and colony formation in oral squamous cell carcinoma (OSCC) . MiRNAs also play an important role in the ceRNA network through combining with target mRNA, inhibiting the action of mRNA expression . MiR-20a has been shown to be aberrantly expressed in BC and regulated cancer aggressiveness by target genes. MiR-20a-5p was highly expressed in both triple-negative breast cancer (TNBC) tissues and cell lines, and promoted the growth of TNBC cells through targeting Runt-related transcription factor 3 (RUNX3) . High mobility group AT-hook 2 (HMGA2) was a target of miR-20a-5p, which significantly induced carcinogenesis of BC . Thus, the molecular mechanism was further clarified that PTENP1 acted as a ceRNA of miR-20a in BC progression. In the ceRNA network constructed in this paper, we found that PTENP1 expression was inversely correlated to miR-20a level in BC cell lines and patients. MiR-20a bound to PTENP1 in a sequence-specific manner and regulated PTENP1 expression. On the other hand, miR-20a was negatively correlated with PTEN level. Moreover, PTEN was a direct target of miR-20a and could be regulated by either miR-20a overexpression or inhibition. Additionally, altered level of PTENP1 and miR-20a was significantly associated with PTEN expression, and impacted BC malignancy. These results provide additional evidence to the reciprocal repression loop of PTENP1/miR-20a/PTEN in a functional aspect of BC development.
PI3K is responsible for coordinating a diverse range of cellular functions, including proliferation, cell survival, degradation and cell migration . As a key oncogentic signaling pathway, PI3K/Akt pathway plays a pivotal role in the development of many cancers, including BC . Additionally, NF-κB showed critical modulation on tumor cells malignancy and progression by regulating numerous genes transcriptionally. Although the involvement of PI3K/Akt pathway in BC has been declared, PTENP1-miR-20a-PTEN network mediated the signaling cascade has not been fully explained so far. In this present study, we found that PTEN level was regulated by PTENP1 and miR-20a, whereas PTEN participated in suppressing the proliferation of cancer cells via negatively regulating the PI3K/Akt pathway [25, 26], which suggested that PTEN was important in malignant transformation of cancer cells. In agreement with these observations, this study showed that altered PTENP1 and miR-20a could effectively influence the expression of PI3K/Akt pathway molecules via PTEN levels. On the other hand, treatment with LY294002 or siAkt signifcantly inhibited the phosphorylation of PI3K/Akt. As expected, the cell colony formation and invasion were attenuated in BC cells treated with LY294002 or siAkt. It was reasonable to conclude that the regulatory effects of PTENP1/miR-20a/PTEN crosstalk on cell aggressiveness could at least be partially mediated via PI3K/Akt pathway.
In conclusion, PTENP1, a tumor suppressor, was low in BC tissues and cell lines, and has the potential to be a prognostic biomarker of BC. Moreover, PTENP1 was discovered to act as a sponge for miR-20a, regulating the downstream PTEN/PI3K/Akt pathway. PTENP1 mediated cell proliferation, metastasis, apoptosis and chemoresistance by endogenously competing with miR-20a through PTEN via PI3K/Akt pathway in BC. The results suggest that PTENP1 may be used as a novel target for clinical diagnosis and therapeutic application of BC.
Availability of data and materials
Source data and reagents are available from the corresponding author upon reasonable request.
Long non-coding RNAs
Anderson BO, Braun S, Lim S, Smith RA, Taplin S, Thomas DB. Global summit early detection panel: Early detection of breast cancer in countries with limited resources. Breast J. 2003;9(Suppl 2):S51–9.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Ca-a Cancer J Clinicians. 2016;66:7–30.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–26.
Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. The emergence of lncRNAs in Cancer biology. Cancer Discovery. 2011;1:391–407.
Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011;147:382–95.
Li RK, Gao J, Guo LH, Huang GQ, Luo WH. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer. Cancer Gene Ther. 2017;24:309–15.
Zhang R, Guo Y, Ma Z, Ma G, Xue Q, Li F, Liu L. Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget. 2017;8:26079–89.
Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.
Wei H, Cui R, Bahr J, Zanesi N, Luo Z, Meng W, Liang G, Croce CM. miR-130a deregulates PTEN and stimulates tumor growth. Cancer Res. 2017;77:6168–78.
Jiang Y, Chang H, Chen G. Effects of microRNA-20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway. Oncol Lett. 2018;15:10001–7.
Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. Mol Cancer. 2018;17:37.
Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465:1033–U1090.
Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, Chen K, Xiao H, Li H, Tang K, Ye Z, Huang Q, Xu H. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther. 2014;13:3086–97.
Li N, Miao Y, Shan Y, Liu B, Li Y, Zhao L, Jia L. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death Dis. 2017;8:e2796.
Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou H, Jia L. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep. 2017;7:41942.
Qian YY, Li K, Liu QY, Liu ZS. Long non-coding RNA PTENP1 interacts with miR-193a-3p to suppress cell migration and invasion through the PTEN pathway in hepatocellular carcinoma. Oncotarget. 2017;8:107859–69.
Liu J, Xing Y, Xu L, Chen W, Cao W, Zhang C. Decreased expression of pseudogene PTENP1 promotes malignant behaviours and is associated with the poor survival of patients with HNSCC. Sci Rep. 2017;7:41179.
Gong T, Zheng S, Huang S, Fu S, Zhang X, Pan S, Yang T, Sun Y, Wang Y, Hui B, Guo J, Zhang X. PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis. Mol Carcinog. 2017;56:2610–9.
Gao L, Ren W, Zhang L, Li S, Kong X, Zhang H, Dong J, Cai G, Jin C, Zheng D, Zhi K. PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of Oral squamous cell carcinoma. Mol Carcinog. 2017;56:1322–34.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.
Bai X, Han G, Liu Y, Jiang H, He Q. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3. Biomed Pharmacother. 2018;103:1482–9.
Zhao W, Geng D, Li S, Chen Z, Sun M. LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer Med. 2018;7:842–55.
Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27:5527–41.
Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17:34.
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.
We would like to acknowledge the editors and reviewers for the helpful comments on this paper.
Thank you for the support of the Liaoning Education Department Science and Technology Research Project (L2016010).
Ethics approval and consent to participate
The study has been examined and certified by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (Ethics Reference NO: YJ-KY-FB-2017-32), and informed consent was obtained from all participants included in the study, in agreement with institutional guidelines.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure S1. Detailed information of PTENP1. (A) The predicted PTENP1 length was around 3.9kb by lncrnadb. (B) PTENP1 was predicted as non-coding RNA by ORF Finder and PhyloCSF analysis. (JPG 787 kb)
Figure S2. SiAkt treatment induced highly apoptotic cell rates compared with the siSCR group. (JPG 265 kb)
About this article
Cite this article
Gao, X., Qin, T., Mao, J. et al. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. J Exp Clin Cancer Res 38, 256 (2019) doi:10.1186/s13046-019-1260-6
- Breast cancer
- PI3K/AKT pathway